Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 330 participants.

Also called NCT07220759

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 330 participants (planned count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07220759
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Canada, Croatia, Czechia, Hungary, Romania, Slovakia, South Korea, Switzerland, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07220759. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-05 (actual); primary completion 2027-05-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Acronym
RENEW 2
Condition
Overweight
Condition
Obesity
Intervention (Drug)
Cagrilintide
Intervention (Drug)
Placebo (matched to Cagrilintide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct07220759
Content hash
52d5ab968f0de845a676a6badd22f5efdd52af57aeffd25a7e23ae718971f731